Autoimmune uveitis Market: Epidemiology, Therapies, Companies, DelveInsight | Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc.

Autoimmune uveitis therapies such as YUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and others are expected to boost the Autoimmune uveitis Market in the upcoming years.

DelveInsight has launched a new report on "Autoimmune uveitis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Autoimmune uveitis, historical and forecasted epidemiology as well as the Autoimmune uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover more about autoimmune uveitis, treatment algorithms, therapies @ https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Autoimmune uveitis Market Report:

The Autoimmune Uveitis market across the 7MM was valued at approximately USD 1,290 million in 2022, with expectations for significant growth by 2034 at a notable CAGR. Among the 7MM, the US had the highest market size in 2022, reaching around USD 840 million, while Italy had the lowest at USD 39 million, both projected to grow by 2034.
The US had the largest share of Autoimmune Uveitis patients, followed by the EU4 countries, the UK, and Japan. The distribution of different subtypes of autoimmune uveitis affects treatment strategies, prognosis, and resource allocation in healthcare systems.
Anterior noninfectious uveitis (aNIU) had the highest number of diagnosed prevalent cases during the study period, followed by Pan-Uveitis and Posterior Uveitis across the 7MM.
HUMIRA is currently the only FDA-approved biologic for this condition. Biologics comprise the largest portion of the Autoimmune Uveitis market, contributing to about USD 960 million of the total market in 2022 across the 7MM.
The market for autoimmune uveitis treatments is expected to grow during the forecast period, driven by emerging therapies such as TRS01, OCS-02, and EYS606.
In 2022, the EU4 countries and the UK together had 0.26 million diagnosed cases of autoimmune uveitis. Germany had the highest number of diagnosed cases in Europe that year, with 73,000 cases. Japan represented 17% of the total diagnosed cases of autoimmune uveitis across the 7MM, with 0.1 million cases in 2022.
Key Autoimmune uveitis companies such as Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others are evaluating new drugs for Autoimmune uveitis to improve the treatment landscape.
Promising Autoimmune uveitis therapies include YUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and others.
Key benefits of the Autoimmune uveitis market report:
Autoimmune uveitis market report covers a descriptive overview and comprehensive insight of the Autoimmune uveitis Epidemiology and Autoimmune uveitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Autoimmune uveitis market report provides insights on the current and emerging therapies.
Autoimmune uveitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Autoimmune uveitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autoimmune uveitis market.

Got queries? Click here to know more about the Autoimmune uveitis Market Landscape https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autoimmune uveitis Overview

Autoimmune uveitis is an inflammatory condition affecting the uveal components of the eye, caused either by an autoimmune reaction to self-antigens or by an innate inflammatory response triggered by an external factor. It can occur as a standalone condition or be associated with a systemic autoimmune or auto-inflammatory disease.

Typically, it affects the uvea but can also involve other parts of the eye. Autoimmune uveitis is classified as either infectious or noninfectious. Noninfectious uveitis (NIU) may occur alongside systemic autoimmune diseases or be localized to the eye. Symptoms of NIU include eye pain, light sensitivity (photophobia), tearing, and redness. General symptoms of uveitis can include blurred vision, light sensitivity, eye pain, floaters, headache, and conjunctival injection. Children may sometimes show no symptoms.

Autoimmune uveitis Market Outlook

Treating noninfectious uveitis (NIU) and other autoimmune-related diseases is rarely straightforward, as it involves more than just blocking a single molecule or flipping a simple switch. However, in recent years, targeted biologic treatments, including HUMIRA, have been approved for autoimmune conditions, some specifically for NIU.

Local treatments for NIU typically include corticosteroids, but other agents like sirolimus and methotrexate have been studied for intraocular injection. Approved local therapies currently available include topical steroids, short-acting intra- and periocular steroids like triamcinolone acetonide, and sustained-release intravitreal implants such as OZURDEX and YUTIQ.

The introduction of new treatments for autoimmune uveitis, including TRS01 eye drops for noninfectious anterior uveitis, OCS-02 for acute anterior uveitis, and EYS606 (a combination product for chronic noninfectious uveitis), is expected to positively impact the autoimmune uveitis market.

Explore how the autoimmune uveitis market is rising @ https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autoimmune uveitis marketed drugs:

YUTIQ: Eyepoint Pharmaceuticals
HUMIRA (Adalimumab): AbbVie Inc.

Autoimmune uveitis emerging drugs:

TRS01: Tarsier Pharma
OCS-02: Oculis Pharma

Scope of the Autoimmune uveitis Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Autoimmune uveitis Companies: Tarsier Pharma, Eli Lilly and Company, Oculis Pharma, Eyevensys, Priovant Therapeutics, Inc., and others
Key Autoimmune uveitis Therapies: IYUTIQ, HUMIRA (Adalimumab), TRS01, OCS-02, and others
Autoimmune uveitis Therapeutic Assessment: Autoimmune uveitis current marketed and Autoimmune uveitis emerging therapies
Autoimmune uveitis Market Dynamics: Autoimmune uveitis market drivers and Autoimmune uveitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Autoimmune uveitis Unmet Needs, KOL's views, Analyst's views, Autoimmune uveitis Market Access and Reimbursement

Request for a sample report @ https://www.delveinsight.com/sample-request/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Autoimmune uveitis Patient Share (%) Overview at a Glance
5. Autoimmune uveitis Market Overview at a Glance
6. Autoimmune uveitis Disease Background and Overview
7. Autoimmune uveitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Autoimmune uveitis
9. Autoimmune uveitis Current Treatment and Medical Practices
10. Unmet Needs
11. Autoimmune uveitis Emerging Therapies
12. Autoimmune uveitis Market Outlook
13. Country-Wise Autoimmune uveitis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Autoimmune uveitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Autoimmune uveitis Market Outlook 2034 https://www.delveinsight.com/report-store/autoimmune-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Autoimmune uveitis Pipeline Insights, DelveInsight

"Autoimmune uveitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune uveitis market. A detailed picture of the Autoimmune uveitis pipeline landscape is provided, which includes the disease overview and Autoimmune uveitis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.